Literature DB >> 11267977

Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer.

G B Wisman1, A J Knol, M N Helder, M Krans, E G de Vries, H Hollema, S de Jong, A G van der Zee.   

Abstract

We investigated, in cervical cancer, the relation between telomerase activity, telomerase RNA (hTR) and mRNA of the catalytic subunit of telomerase, hTERT, with "classic" clinicopathological factors as well as survival. Frozen specimens were obtained from 107 consecutive patients with cervical cancer, treated with surgery or radiotherapy with or without chemotherapy. Telomerase activity was determined with fluorescence-based TRAP and hTR and hTERT with semi-quantitative RT-PCR. Eight normal cervical specimens served as controls. Analysis of prognostic factors and survival was limited to early-stage patients, treated primarily with radical hysterectomy. Telomerase activity was not detected in normal cervices and was present in 85 of 107 (79%) cervical cancers (p < 0.001). hTR was detected in all normal cervices and cervical cancers, while hTERT mRNA was detected in 1 of 8 (13%) normal cervices and in 83 of 104 (80%) cervical cancers (p < 0.001). In contrast to semi-quantitative hTR expression levels, semi-quantitative hTERT mRNA levels were related to telomerase activity levels (p < 0.01). In all patients, telomerase activity levels were related to differentiation grade (p < 0.05) but not to stage and histotype. In early-stage patients, telomerase activity, hTR and hTERT were not related to tumor volume, vascular invasion or presence of metastatic lymph nodes. Tumor volume, vascular invasion and presence of metastatic lymph nodes were related to (progression-free) survival, while telomerase activity and its subunits were not. Frequent up-regulation of telomerase activity and hTERT mRNA is especially observed in cervical cancers, while hTR is also detected in normal cervices. Telomerase is not applicable as a prognostic factor in early-stage cervical cancer patients. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267977     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1099>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Telomerase as a potential marker for early diagnosing cervical carcinoma.

Authors:  D A Skvortsov; N M Gasparian; M P Rubtsova; M E Zvereva; M D Fedorova; L S Pavlova; A A Bogdanov; O A Dontsova; F L Kisseljov
Journal:  Dokl Biochem Biophys       Date:  2006 May-Jun       Impact factor: 0.788

2.  Cervical epithelial cells transduced with the papillomavirus E6/E7 oncogenes maintain stable levels of oncoprotein expression but exhibit progressive, major increases in hTERT gene expression and telomerase activity.

Authors:  Astrid C Baege; Allison Berger; Robert Schlegel; Tim Veldman; Richard Schlegel
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

3.  Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears.

Authors:  Kevin A Ault; Heather K Allen; Stacia L Phillips; M Bridget Zimmerman; Aloysius J Klingelhutz
Journal:  J Low Genit Tract Dis       Date:  2005-04       Impact factor: 1.925

4.  Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-Azacytidine in HeLa and SiHa cervical cancer cell lines.

Authors:  Swati Sood; Radhika Srinivasan
Journal:  Mol Cell Biochem       Date:  2015-03-14       Impact factor: 3.396

5.  Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.

Authors:  Alpana Sharma; Medha Rajappa; Alpana Saxena; Manoj Sharma
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.

Authors:  Xing Fan; Yunyue Wang; John Kratz; Dan J Brat; Yves Robitaille; Albert Moghrabi; Elizabeth J Perlman; Chi V Dang; Peter C Burger; Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

Review 7.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

8.  Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer.

Authors:  U Kailash; C C Soundararajan; R Lakshmy; R Arora; S Vivekanandhan; B C Das
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

9.  Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer.

Authors:  Hui Yang; Hongyan Zhang; Yahua Zhong; Qiaoli Wang; Lei Yang; Hong Kang; Xiaojia Gao; Haijun Yu; Conghua Xie; Fuxiang Zhou; Yunfeng Zhou
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

10.  Change of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.

Authors:  Byung Joo Lee; Bae Hyuk Lee; Soo Geun Wang; Jin Choon Lee; Hwan Jung Roh; Eui Kyung Goh; Cheol Min Kim; Eun Sook Jun
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.